IGF-1 LR3
Modified Growth Factor Analog | Research Chemical Only
On this page
What is IGF-1 LR3?
IGF-1 LR3 is a lab-modified version of a natural growth-factor protein the body already makes, engineered to stay active in solution longer than the native form. It has never been tested in human clinical trials, and researchers have only studied it in animal models looking at cell-growth and metabolism pathways. It's sold here strictly as a research chemical for laboratory study — it has never been approved for human use in any country.
Key terms:
IGF-1 LR3 is a synthetic analog of igf-1.
IGF-1 LR3 is a lab-made 83-amino acid analog of human insulin-like growth factor-1. It has never been approved for human use in any country. It is roughly 3x more potent than native IGF-1, with a 20-30 hour half-life, because it interacts less with IGF-binding proteins. Even so, no human clinical trials have ever been conducted. The compound is prohibited in competitive sports. It carries significant risks, including severe hypoglycemia (dangerously low blood sugar) and cancer proliferation. It remains strictly a research chemical for laboratory use only.
Key research areas
- Approximately 3x more potent than native IGF-1
- 20-30 hour half-life due to reduced IGFBP binding
- Promotes both muscle hypertrophy and hyperplasia in animal models
- Preserves lean mass in cachexia models through ubiquitin-proteasome inhibition
- Unique ability to create new muscle fibers via satellite cell differentiation
Researched dosing
This table reflects how researchers have structured laboratory study designs with IGF-1 LR3 in published animal research — presented as research-methodology reference, not usage instructions.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Lower-dose study protocol | 20-30mcg | Once daily, post-workout | Subcutaneous injection |
| Mid-dose study protocol | 40-60mcg | Once daily, post-workout or morning | Subcutaneous or intramuscular |
| Higher-dose study protocol | 80-100mcg | Once daily or split AM/PM | Subcutaneous or site-specific IM |
| Study protocol in women | 10-20mcg | Once daily | Subcutaneous only |
Commonly cycled 6 weeks on, 4+ weeks off.
How it works
At the cell level, IGF-1 LR3 research looks at how the modified protein binds growth-factor receptors and activates cell-growth signaling pathways — the receptor and pathway names below are simply the biology terms for that process.
Full IGF-1 receptor agonist with reduced IGF-binding protein interaction. N-terminal extension and R3 substitution prevent sequestration, maintaining free circulating levels. Activates PI3K/Akt/mTOR and MAPK/ERK pathways.
Molecular data
These figures — molecular weight, chain length — are the chemistry fingerprint researchers use to confirm a sample is IGF-1 LR3, an engineered 83-amino-acid analog of a natural growth factor.
- Weight
- 2888 Da
- Length
- 83 amino acids
- Type
- Synthetic analog of IGF-1
Research applications
This section lists the body systems and research areas scientists have studied for IGF-1 LR3 in animal models — a summary of what's been studied in the literature, not medical claims about people; no human clinical trial has ever been conducted.
Muscle Development
Animal studies show 15-20% lean mass gains in 4 weeks through satellite cell activation and protein synthesis enhancement. No human data exists. Preserves lean mass in cachexia models through ubiquitin-proteasome inhibition. Cancer cachexia rats maintained 30% more muscle versus placebo. Unique ability to create new muscle fibers via satellite cell differentiation, not just enlarging existing fibers. Permanent structural changes possible.
Tissue Repair
Research into tissue repair and regeneration applications in animal models.
Metabolic
Metabolic effects including insulin sensitivity and glucose regulation in research settings.
Dosage reference
- Doses used in research
- 20–40 mcg in lower-dose research protocols
- Frequency in studies
- Once daily post-workout
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- Initial: 1-2 weeks. Notable: 2-4 weeks. Desensitization: 6 weeks.
- Storage
- Lyophilized: -20°C long-term. Reconstituted in acetic acid: 2-8°C up to 1 year. In bac water: 7 days max.
- Cycle length
- 4-6 weeks maximum
- Break between cycles
- Equal or longer off-cycle (4-6+ weeks) for receptor recovery
Interactions
This list shows which other compounds researchers have studied alongside IGF-1 LR3 in animal and preclinical research, and flags pairings that call for extra caution.
Reconstitution & storage
This is the standard laboratory method for turning freeze-dried IGF-1 LR3 powder into a liquid research solution, following the same basic mixing process used for most peptide research.
- Equilibrate vial to room temperature (15-30 min)
- Sanitize rubber stopper with alcohol
- Calculate concentration (e.g., 1mg in 2mL = 500mcg/mL)
- Draw calculated volume of 0.6% acetic acid solution
- Inject slowly along vial wall, not directly on powder
- Gently swirl - never shake vigorously
- Allow to dissolve completely (2-5 min)
- Store the reconstituted solution refrigerated (2–8°C), labeled with the date and concentration, for laboratory research use only.
Lyophilized: -20°C long-term, use within Stable long-term at -20°C; ships at room temperature but refrigerate immediately upon arrival
Reconstituted: 2-6°C, use within In acetic acid: up to 1 year; In BAC water: 7 days max
Open the IGF-1 LR3 reconstitution calculatorQuality indicators
These are the checks researchers use — purity testing, appearance, storage — to confirm an IGF-1 LR3 sample is correctly identified before use in a study, alongside the Certificate of Analysis (COA).
Research Chemical Status - Never approved for human use. Zero human clinical trials. All use represents uncontrolled experimentation.
Severe Hypoglycemia Risk - Can cause life-threatening low blood sugar lasting 20-30 hours. Multiple animal deaths documented in studies.
Cancer Proliferation Concern - UK Biobank study links elevated IGF-1 to multiple cancers. May accelerate growth of existing tumors.
Purity Testing Essential - Require HPLC >95% and mass spectrometry confirmation. Black market samples often degraded or contaminated.
Species-Specific Responses - Works in rats, fails in guinea pigs, inhibits growth in pigs. Human response entirely unknown.
Proper Cold Storage Required - Lyophilized powder stable at -20°C. Ships at room temperature but refrigerate immediately upon arrival.
What to expect
This timeline summarizes what animal-model research literature has reported at each stage of a study — research context for comparing studies, not a personal-results promise.
Increased pump, fullness, possible hypoglycemia episodes if carbs inadequate
Enhanced recovery, strength gains, visible muscle fullness, possible water retention
Maximum effects but approaching receptor desensitization. Joint stiffness common.
Gradual loss of pumps over 1-2 weeks. Strength/size gains may persist if training maintained.
Safety notes
This section covers how IGF-1 LR3 is regulated and handled in a laboratory setting — it has never been approved for human use in any country, and this is research-use-only scope, not medical safety advice.
- Contraindicated with any cancer history or undiagnosed growths
- May cause organ hypertrophy (heart, intestines) with prolonged use
- Never inject before sleep - overnight hypoglycemia risk
- Monitor blood glucose regularly, especially first week
- WADA prohibited - will cause failed drug test in athletes
- Never approved for human use in any country - strictly a research chemical
Regulatory status
- Not approved by the FDA for any indication.
- Prohibited by the World Anti-Doping Agency (WADA).
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
Frequently asked questions
What is IGF-1 LR3?
IGF-1 LR3 is a synthetic 83-amino-acid analog of human insulin-like growth factor-1, engineered so it interacts less with IGF-binding proteins and stays active in solution longer than the native form. It has never been approved for human use in any country, and researchers have studied it only in animal and cell models. Lux BioPure supplies it strictly as a research chemical for laboratory study.
What class of compound is IGF-1 LR3?
IGF-1 LR3 is classified as a synthetic analog of IGF-1 — a modified growth-factor protein of 83 amino acids with a molecular weight near 2,888 daltons. In research it is described as a full IGF-1 receptor agonist whose N-terminal extension and R3 substitution reduce binding-protein sequestration; those are neutral biochemical descriptions of the molecule, with no human outcome attached.
How is IGF-1 LR3 typically reconstituted for research use?
Unlike many peptides, lyophilized IGF-1 LR3 is usually reconstituted with a dilute (about 0.6%) acetic acid solution rather than plain bacteriostatic water. The vial is first equilibrated to room temperature, the diluent is added slowly along the vial wall, and the vial is gently swirled — never shaken — until fully dissolved. This is standard laboratory methodology, not a usage instruction.
How should reconstituted IGF-1 LR3 be stored in the lab?
Lyophilized IGF-1 LR3 is stable long-term at -20°C; it may ship at room temperature but should be refrigerated on arrival. Once reconstituted, an acetic-acid solution can remain usable refrigerated for up to about a year, whereas a bacteriostatic-water solution is limited to roughly seven days. Researchers verify a sample with HPLC purity above 95% and mass-spectrometry confirmation.
Is IGF-1 LR3 legal to purchase for research in Canada?
Lux BioPure sells IGF-1 LR3 in Canada strictly as a research-use-only chemical for laboratory study — it is not for human or veterinary use and is not offered as a drug or supplement. It has never been approved for human use in any country and appears on the World Anti-Doping Agency prohibited list, so it is not permitted for competitive athletes.
References
Demonstrated 2.5x greater anabolic response compared to native IGF-1. Satellite cell activation and protein synthesis increased by 50% above baseline. Both hypertrophy and hyperplasia observed.
Acute infusion suppressed insulin secretion by 66%. Chronic infusion caused 4 animal deaths from hypoglycemia and hypoxemia. Significantly reduced circulating amino acids, particularly BCAAs.
View StudyContrary to expectations, decreased average daily gain and food intake. Reduced plasma IGFBP-3, IGF-1, and insulin. Growth hormone dropped 23% with 60% reduction in pulse area.
View Study